Navigation Links
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Date:9/12/2007

FRIMLEY, England, September 13 /PRNewswire-FirstCall/ --

- Physicians Welcome New Option for Potentially Life Threatening Disease

- Daptomycin has a Rapidly Bactericidal Mode of Action

The launch of daptomycin for the treatment of both methicillin-sensitive and resistant Staphylococcus aureus (MSSA and MRSA) bloodstream infections (bacteraemia) and heart infections (right-sided infective endocarditis) has been announced today by Novartis Pharmaceuticals UK Ltd.(1) Daptomycin, one of only two new classes of antibiotic in over 20 years, has been shown to be as effective as existing agents in treating a range of serious Gram-positive infections, offering an important new option for healthcare professionals.

MRSA is a frequent cause of bacteraemia and is associated with serious complications, including endocarditis (in 30-40% of cases) and has a high mortality rate.(2) Over 7,000 people each year contract bacteraemia and the incidence is rising.(3) From 1993 to 2005 the number of deaths increased from 51 to 1,629.(4) There is evidence that some strains of MRSA are developing resistance to existing antibiotic options.(5) Daptomycin, which is rapidly bactericidal, has a specific mode of action, which reduces the likelihood of resistance developing. Daptomycin's once daily dosing and tolerability profile, with no need for therapeutic drug monitoring, has the potential to simplify the management of patients with complicated infections.

Dr Andrew Seaton, consultant in infectious diseases, Gartnavel general hospital, Glasgow welcomed the news, commenting; "Serious staphylococcal infections are extremely challenging for hospital specialists to treat, with about 40% in the UK now resistant to first line therapy. Daptomycin is a fast acting agent in these potentially difficult situations and is well tolerated by patients. This is an extremely important and welcomed development in the battle against serious MRSA infection."

Daptomycin is
'/>"/>

SOURCE Novartis Pharmaceuticals UK Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)...  "Everybody is affected by cancer sooner or later," ... brutal. We,ve got to get away from that."  If ... a loved one or friend battling for their life ... and other treatments cause the human body. It,s almost ... and succumb to the disease. Dr. Dionne has developed ...
(Date:4/20/2015)... 20, 2015 /CNW/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... study that showed one of its proprietary human-derived CPP ... tissue through inhibition of NFkB signalling even if administered ... permeability of the blood brain barrier (BBB) in mice ...
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, ... using its proprietary technology, today announced presentation of data ... the development of antibody-drug conjugates (ADCs). The data were presented ... taking place April 18-22 in Philadelphia ... these data which point to the many commercial applications ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... May 17, 2011 Amgen (NASDAQ: AMGN ... 3 trial (,147) demonstrating that XGEVA™ (denosumab) significantly increased ... men with castrate-resistant metastatic prostate cancer that has not ... study were presented for the first time today in ...
... DIEGO, May 17, 2011 P ... that it has submitted a Biologics Master File (BMF) to ... grade CRM197 carrier protein to support the development of conjugate ... Proteins is supplying cGMP grade CRM197 carrier protein to multiple ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company successfully showcased ... ("the fair") recently held in Chengdu, China. ...
Cached Biology Technology:Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 2Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 3Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 4Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 5Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 6Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 7Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 8Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 9Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... the worlds of law, geography, economics, public health ... College London) on Friday September 19th to examine ... locally-rooted champions for global sustainability, reaching out to ... change. The symposium, which is called: "The Sustainable ...
... no such thing as a ,safe, tan based on ultraviolet ... the October issue of Pigment Cell & Melanoma Research ... Cell Societies (IFPCS) and the Society for Melanoma Research. ... in the fields of cell biology, dermatology and epidemiology ...
... the U.S. Environmental Protection Agency (EPA) have made ... Implications of Nanotechnology (CEIN). The centers, led ... nanomaterials interact with the environment and with living ... assessment and mitigation strategies useful in the development ...
Cached Biology News:Universities develop a more sustainable future 2More than skin deep: There's no such thing as a 'safe' suntan, researchers warn 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 3NSF and EPA establish 2 centers for environmental implications of nanotechnology 4
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: